ALNY Company Profile and Key Details

Q: Who are the executives of ALNY?

Mr. Mark BaglinVice President of Global MarketingMr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Michael W. Bonney B.A.Executive ChairmanDr. Akshay K. Vaishnaw M.D., Ph.D.PresMr. Tolga Tanguler M.B.A.Executive Vice President & Chief Commercial OfficerDr. Alfred W. Boyle Ph.D.Chief Technical Operations & Quality OfficerMr. Timothy J. MainesChief Technical Operations & Quality OfficerMs. Christine Regan LindenboomSenior Vice President of Investor Relations & Corporation CommunicationsDr. Yvonne L. Greenstreet M.B.A., MBA, MBChBChief Executive Officer & DirectorMs. Indrani M. Lall Franchini J.D.Executive Vice President, Chief Legal Officer & Sec.Mr. Jeffrey V. Poulton M.B.A.Chief Financial Officer & Executive Vice PresidentDr. Pushkal P. Garg M.D.Chief Medical Officer and Executive Vice President of Devel. & Medical AffairsDr. Kevin Joseph Fitzgerald Ph.D.Senior Vice President, Head of Research & Chief Scientific Officer

NASDAQ : ALNY

Alnylam Pharmaceuticals

$294.06

5.88+2.04%

At Close 4:00 PM

61.45

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Alnylam Pharmaceuticals, Inc. (ALNY) stock surged +2.04%, trading at $294.06 on NASDAQ, up from the previous close of $288.18. The stock opened at $290.95, fluctuating between $288.85 and $303.46 in the recent session.

Stock Snapshot

288.18

Prev. Close

39.26B

Market Cap

288.85

Day Low

52.98

P/E Ratio

5.55

EPS (TTM)

0.33

Cash Flow per Share

290.95

Open

133.51M

Number of Shares

303.46

Day High

96.24%

Free Float in %

-1.76

Book Value

1.27M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 24, 2026	290.95	303.46	288.85	294.06	1.3M
Jun 23, 2026	290.89	291.95	285.26	288.18	1.04M
Jun 22, 2026	278.42	286.67	278.17	286.41	1.42M
Jun 18, 2026	280.11	282.98	273.11	278.09	2.16M
Jun 17, 2026	281.31	288.00	277.78	282.72	1.32M
Jun 16, 2026	288.13	288.48	276.94	281.90	1.21M
Jun 15, 2026	282.92	288.11	281.36	287.80	1.1M
Jun 12, 2026	288.96	291.28	281.77	282.85	1.41M
Jun 11, 2026	290.70	292.98	285.22	289.39	1.05M
Jun 10, 2026	297.69	299.70	290.53	291.22	927.18K
Jun 09, 2026	297.31	302.85	293.97	297.69	1.26M
Jun 08, 2026	303.11	303.57	285.54	292.16	1.65M
Jun 05, 2026	306.34	306.73	300.50	303.05	986.21K
Jun 04, 2026	297.22	310.53	293.85	303.64	1.08M
Jun 03, 2026	284.48	293.16	283.10	292.58	951.08K
Jun 01, 2026	299.51	303.98	295.13	295.63	1.03M
May 29, 2026	302.43	305.68	297.62	301.98	2.27M
May 28, 2026	293.00	305.98	291.84	305.06	1.02M
May 27, 2026	293.40	299.98	292.91	295.63	629.46K
May 26, 2026	299.00	301.09	294.26	295.50	649.71K

Contact Details

Cambridge, MA 02142

United States

https://www.alnylam.com 617 551 8200

About Company

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Stock Peers

ARGX

-0.9-0.11%

argenx SE$852.50 REGN

5.4+0.87%

Regeneron Pharmaceuticals, Inc.$623.43 UTHR

5.57+1.02%

United Therapeutics Corporation$549.90 MDGL

-3.67-0.71%

Madrigal Pharmaceuticals, Inc.$509.76 VRTX

6.78+1.45%

Vertex Pharmaceuticals Incorporated$475.20 KRYS

7.42+2.18%

Krystal Biotech, Inc.$347.63 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

3.57+1.17%

Praxis Precision Medicines, Inc.$308.94 LGND

5.47+1.96%

Ligand Pharmaceuticals Incorporated$284.91 ASND

-0.58-0.24%

Ascendis Pharma A/S$238.01

Company Overview

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $294.06 USD, gaining $5.88 (2.04%) from the previous close of $288.18. The stock is currently mid-range between its 52-week high and low $273.11 and $495.55. With a market capitalization of about $39.26 billion, Alnylam Pharmaceuticals, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 1.12 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yvonne L. Greenstreet, the company employs approximately 2,230 people and listed since June 01, 2004. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology.

Technical Performance

ALNY has shown weak momentum, losing -4.15% over the past week and -26.19% over the past quarter, though year-to-date performance is down -10.59%. Short-term trend indicators are bullishly aligned (SMA20 -0.18%, SMA50 -8.87%, SMA200 -15.06%). The stock’s 14-day RSI is 43.29 (neutral), while the ATR of 13.1 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -33.16% below its high and over 60.9% above its low. Average 10-day trading volume of 1.36 million shares is slightly above the 3-month average of 1.12 million, indicating heightened recent market interest.

Valuation Metrics

Alnylam Pharmaceuticals, Inc. trades at a P/E ratio of 68.81, slightly above the S&P 500 average, with a price-to-sales ratio of 9.34 and a price-to-book ratio of 37.07 reflecting a rich premium to book value. The P/FCF stands at 62.45, also above market averages. Compared to sector medians, Alnylam Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Alnylam Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $213.78. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 84.85% annually over the next five years. The latest quarter delivered EPS of $1.51. The next quarter is forecast at $0.99. Next year's EPS is expected at -$21.13. Analyst sentiment is bullish. Analyst rating data shows there are 17 Strong Buy ratings, 35 Buy ratings, 10 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $583.00 to $330.00. The high target offers 98.26% upside. The low target suggests 12.22% downside. The mean target is $465.34. This offers 58.25% upside. Alnylam Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by 68.72%. The prior quarter beat by -29.31%. Over the last six quarters, Apple has recorded several small beats. These include -109.68% in February 13, 2025.

Shareholding & Insider Activity

Alnylam Pharmaceuticals, Inc. has 133.51 million shares outstanding. The public float is 132.94 million shares, elevated short interest at 5.29% of float. This equals 5.30 million shares. The short ratio is 4.89 days. Institutional investors hold 101.74% of the float. Insiders own 1.47%. Greenstreet Yvonne holds 95.70 thousand shares, Poulton Jeffrey V. has 61.80 thousand shares and Tanguler Tolga has 34.30 thousand shares. Over the past six months, insider transactions show net selling. They sold 20.82 thousand shares across 30 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Alnylam Pharmaceuticals generated $1.83B in revenue, or $14.64 per share. Gross margin was 83.02%, operating margin -15.43%, and net profit margin -24.08%. Returns are negative, with ROA at -11.49% and ROE at 199.53%.
On valuation metrics, Alnylam Pharmaceuticals trades at a P/E of 68.81, P/S of 9.34 and P/B of 37.07. The current ratio is 3.13 and quick ratio is 3.06. Operationally, the company’s inventory turnover is 9.75 and cash conversion cycle is 56.28 days. Debt-to-equity is 1.18, supported by a cash flow-to-debt ratio of 0.56.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Alnylam Pharmaceuticals posted revenue of $1.83B, down slightly from $1.04B in the prior quarter. Gross profit was $1.52B (margin 83.02%). Operating income was - $282.18M (margin -15.4%). Net income was- $440.24M (EPS - $3.52).
The company ended the quarter with $2.44B in cash and short-term investments, a total debt of $2.68B, and net debt of $1.87B. Total assets were $3.83B, with equity of - $220.64M. Financials further reflected stability, with operating cash flow of $104.16M, free cash flow of $41.95M, and capital expenditures of - $62.21M.

Price Forecast & Outlook

Our AI price prediction model suggests that Alnylam Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.39%, with price expected at $278.20 by July 08, 2026, within a range of $271.89 to $284.82 3-Month Outlook: Projected rise of 42.7%, reaching $419.61 by September 21, 2026, with a range of $414.40 to $425.86. 1-Year Outlook: Projected gain of 26.81%, with price at $372.89 by June 24, 2027, within a range of $351.91 to $395.92.

Key Takeaways

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares are down -10.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Alnylam Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 68.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $338.14, suggesting 14.99% upside. Our AI forecast model points to short-term weakness (-5.39% over two weeks), a medium-term rise (42.7% over three months), and a longer-term gain (26.81% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Alnylam Pharmaceuticals, Inc. (ALNY) stock price?

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock price is $294.06 in the last trading session. During the trading session, ALNY stock reached the peak price of $303.46 while $288.85 was the lowest point it dropped to. The percentage change in ALNY stock occurred in the recent session was 2.04% while the dollar amount for the price change in ALNY stock was $5.88.

ALNY's industry and sector of operation?

The NASDAQ listed ALNY is part of Biotechnology industry that operates in the broader Healthcare sector. Alnylam Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ALNY?

Mr. Mark Baglin
Vice President of Global Marketing
Mr. Piyush Sharma J.D.
Chief Ethics & Compliance Officer
Mr. Michael W. Bonney B.A.
Executive Chairman
Dr. Akshay K. Vaishnaw M.D., Ph.D.
Pres
Mr. Tolga Tanguler M.B.A.
Executive Vice President & Chief Commercial Officer
Dr. Alfred W. Boyle Ph.D.
Chief Technical Operations & Quality Officer
Mr. Timothy J. Maines
Chief Technical Operations & Quality Officer
Ms. Christine Regan Lindenboom
Senior Vice President of Investor Relations & Corporation Communications
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Chief Executive Officer & Director
Ms. Indrani M. Lall Franchini J.D.
Executive Vice President, Chief Legal Officer & Sec.
Mr. Jeffrey V. Poulton M.B.A.
Chief Financial Officer & Executive Vice President
Dr. Pushkal P. Garg M.D.
Chief Medical Officer and Executive Vice President of Devel. & Medical Affairs
Dr. Kevin Joseph Fitzgerald Ph.D.
Senior Vice President, Head of Research & Chief Scientific Officer

How ALNY did perform over past 52-week?

ALNY's closing price is 7.67% higher than its 52-week low of $273.11 where as its distance from 52-week high of $495.55 is -40.66%.

How many employees does ALNY have?

Number of ALNY employees currently stands at 2,230.

Link for ALNY official website?

Official Website of ALNY is: https://www.alnylam.com

How do I contact ALNY?

ALNY could be contacted at phone 617 551 8200 and can also be accessed through its website. ALNY operates from 675 West Kendall Street, Cambridge, MA 02142, United States.

How many shares of ALNY are traded daily?

ALNY stock volume for the day was 1.27M shares. The average number of ALNY shares traded daily for last 3 months was 1.12M.

What is the market cap of ALNY currently?

The market value of ALNY currently stands at $39.26B with its latest stock price at $294.06 and 133.51M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	2230
Beta	0.27
Sales or Revenue	$1.83B
5Y Sales Change%	18.656%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ALNY Company Profile and Key Details

Alnylam Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights